Deng X, Ito T, Carr B, Mumby M, May W S
Sealy Center for Oncology and Hematology and Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas 77555-1048, USA.
J Biol Chem. 1998 Dec 18;273(51):34157-63. doi: 10.1074/jbc.273.51.34157.
Interleukin 3 (IL-3) stimulates the net growth of murine factor-dependent NSF/N1.H7 and FDC-P1/ER myeloid cells by stimulating proliferation and suppressing apoptosis. Recently, we discovered that Bcl2 is phosphorylated at an evolutionarily conserved serine residue (Ser70) after treatment with the survival agonists IL-3 or bryostatin 1, a potent activator of protein kinase (Ito, T., Deng, X., Carr, B., and May, W. S. (1997) J. Biol. Chem. 272, 11671-11673). In addition, an intact Ser70 was found to be required for Bcl2's ability to suppress apoptosis after IL-3 withdrawal or toxic chemotherapy. We now show that phosphorylation of Bcl2 occurs rapidly after the addition of agonist to IL-3-deprived cells and can be reversed by the action of an okadaic acid (OA)-sensitive phosphatase. A role for protein phosphatase (PP) 2A as the Bcl2 regulatory phosphatase is supported by several observations: 1) dephosphorylation of Bcl2 is blocked by OA, a potent PP1 and PP2A inhibitor; 2) intracellular PP2A, but not PP1, co-localizes with Bcl2; 3) the purified PP2Ac catalytic subunit directly dephosphorylates Bcl2 in vitro in an OA-sensitive manner; 4) the purified PP2Ac catalytic subunit preferentially dephosphorylates Bcl2 in vitro compared with PP1 and PP2B; 5) reciprocal immunoprecipitation studies indicate a direct interaction between PP2A and hemagglutinin (HA)-Bcl2; and 6) treatment of factor-deprived cells with bryostatin 1 dramatically increases the association between PP2A and Bcl2. Increased association between Bcl2 and PP2A occurs 15 min after agonist stimulation when Bcl2 phosphorylation has peaked and immediately before dephosphorylation. An agonist-induced increased association of PP2A and Bcl2 fails to occur in cells expressing the inactive, phosphorylation-negative S70A Bcl2 mutant, which indicates that an intact Ser70 site is necessary and sufficient for the interaction to occur. Functional phosphorylation of Bcl2 at Ser70 is proposed to be a dynamic process regulated by the sequential action of an agonist-activated Bcl2 kinase and PP2A.
白细胞介素3(IL-3)通过刺激增殖和抑制凋亡来促进小鼠因子依赖性NSF/N1.H7和FDC-P1/ER髓样细胞的净生长。最近,我们发现用存活激动剂IL-3或苔藓抑素1(一种蛋白激酶的有效激活剂)处理后,Bcl2在一个进化保守的丝氨酸残基(Ser70)处发生磷酸化(伊藤,T.,邓,X.,卡尔,B.,和梅,W.S.(1997年)《生物化学杂志》272,11671 - 11673)。此外,发现完整的Ser70对于Bcl2在IL-3撤除或毒性化疗后抑制凋亡的能力是必需的。我们现在表明,在向缺乏IL-3的细胞中添加激动剂后,Bcl2的磷酸化迅速发生,并且可以被冈田酸(OA)敏感的磷酸酶的作用逆转。蛋白磷酸酶(PP)2A作为Bcl2调节磷酸酶的作用得到了以下几个观察结果的支持:1)OA(一种有效的PP1和PP2A抑制剂)可阻断Bcl2的去磷酸化;2)细胞内的PP2A而非PP1与Bcl2共定位;3)纯化的PP2Ac催化亚基在体外以OA敏感的方式直接使Bcl2去磷酸化;4)与PP1和PP2B相比,纯化的PP2Ac催化亚基在体外优先使Bcl2去磷酸化;5)相互免疫沉淀研究表明PP2A与血凝素(HA)-Bcl2之间存在直接相互作用;6)用苔藓抑素1处理缺乏因子的细胞会显著增加PP2A与Bcl2之间的结合。当Bcl2磷酸化达到峰值且在去磷酸化之前立即,激动剂刺激后15分钟,Bcl2与PP2A之间的结合增加。在表达无活性的、磷酸化阴性的S70A Bcl2突变体的细胞中,激动剂诱导的PP2A与Bcl2结合增加未发生,这表明完整的Ser70位点对于这种相互作用的发生是必要且充分的。Bcl2在Ser70处的功能性磷酸化被认为是一个由激动剂激活的Bcl2激酶和PP2A的顺序作用调节的动态过程。